Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Rocket Pharmaceuticals stock | 32.15

Own Rocket Pharmaceuticals stock in just a few minutes.

Posted

Fact checked

Rocket Pharmaceuticals, Inc is a biotechnology business based in the US. Rocket Pharmaceuticals shares (RCKT) are listed on the NASDAQ and all prices are listed in US Dollars. Rocket Pharmaceuticals employs 84 staff and has a market cap (total outstanding shares value) of USD$1.7 billion.

How to buy shares in Rocket Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Rocket Pharmaceuticals. Find the stock by name or ticker symbol: RCKT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Rocket Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$32.15, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Rocket Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Rocket Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Rocket Pharmaceuticals share price

Use our graph to track the performance of RCKT stocks over time.

Rocket Pharmaceuticals shares at a glance

Information last updated 2020-11-25.
Latest market close USD$32.15
52-week range USD$9.01 - USD$35
50-day moving average USD$29.5536
200-day moving average USD$24.5912
Wall St. target price USD$39.6
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.853

Buy Rocket Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Rocket Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Rocket Pharmaceuticals price performance over time

Historical closes compared with the close of $32.15 from 2020-11-16

1 week (2020-11-17) -6.27%
1 month (2020-10-23) 14.39%
3 months (2020-08-24) 29.17%
6 months (2020-05-23) N/A
1 year (2019-11-23) N/A
2 years (2018-11-23) 113.20%
3 years (2017-11-24) 1,212.24%
5 years (2015-11-24) 190.16%

Rocket Pharmaceuticals financials

Gross profit TTM USD$0
Return on assets TTM -18.63%
Return on equity TTM -41.64%
Profit margin 0%
Book value $4.381
Market capitalisation USD$1.7 billion

TTM: trailing 12 months

Shorting Rocket Pharmaceuticals shares

There are currently 9.7 million Rocket Pharmaceuticals shares held short by investors – that's known as Rocket Pharmaceuticals's "short interest". This figure is 0.6% up from 9.6 million last month.

There are a few different ways that this level of interest in shorting Rocket Pharmaceuticals shares can be evaluated.

Rocket Pharmaceuticals's "short interest ratio" (SIR)

Rocket Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Rocket Pharmaceuticals shares currently shorted divided by the average quantity of Rocket Pharmaceuticals shares traded daily (recently around 285652.76796231). Rocket Pharmaceuticals's SIR currently stands at 33.96. In other words for every 100,000 Rocket Pharmaceuticals shares traded daily on the market, roughly 33960 shares are currently held short.

However Rocket Pharmaceuticals's short interest can also be evaluated against the total number of Rocket Pharmaceuticals shares, or, against the total number of tradable Rocket Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rocket Pharmaceuticals's short interest could be expressed as 0.18% of the outstanding shares (for every 100,000 Rocket Pharmaceuticals shares in existence, roughly 180 shares are currently held short) or 0.2761% of the tradable shares (for every 100,000 tradable Rocket Pharmaceuticals shares, roughly 276 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Rocket Pharmaceuticals.

Find out more about how you can short Rocket Pharmaceuticals stock.

Rocket Pharmaceuticals share dividends

We're not expecting Rocket Pharmaceuticals to pay a dividend over the next 12 months.

Have Rocket Pharmaceuticals's shares ever split?

Rocket Pharmaceuticals's shares were split on a 1:4 basis on 5 January 2018. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rocket Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Rocket Pharmaceuticals shares which in turn could have impacted Rocket Pharmaceuticals's share price.

Rocket Pharmaceuticals share price volatility

Over the last 12 months, Rocket Pharmaceuticals's shares have ranged in value from as little as $9.01 up to $35. A popular way to gauge a stock's volatility is its "beta".

RCKT.US volatility(beta: 1.57)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rocket Pharmaceuticals's is 1.5691. This would suggest that Rocket Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Rocket Pharmaceuticals overview

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction, and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. It also has additional infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site